The size of the North America Capecitabine Market was valued at USD XX Million in 2022 and is expected to reach USD XX Million by 2027 at XX% CAGR during the forecast period 2022 to 2027.
The rising demand for Capecitabine can be attributed to its antimetabolite action, which operates by interfering with DNA synthesis and lowering the severity of side effects. In addition, Capecitabine has been effective and well-tolerated in breast cancer patients when combined with taxane-based chemotherapy drugs like docetaxel (Taxotere) and paclitaxel (Taxol).
As a result, the rising burden of breast cancer and expanding patient awareness of the benefits are projected to drive North American market expansion. In addition, the surge in cancer cases and the patent expiration of Capecitabine have boosted the demand for Capecitabine.
Furthermore, continuous capecitabine research initiatives and a favorable regulatory environment are positive indicators for capecitabine medication demand. The capecitabine market is expected to develop as the prevalence of cancer rises, demand for target medication therapy rises, and Capecitabine's patent expires.
According to the National Cancer Institute, around 135,460 persons in the United States were diagnosed with colon and rectum cancer in 2017, with 50,269 people dying from the disease. Furthermore, rising healthcare expenditures and increased government and private sector investment in cancer treatment or assistance programs such as Cancer Care and Cancer Suraksha Scheme are expected to drive North America's capecitabine market expansion.
Due to severe side effects connected with Capecitabine, the North American capecitabine market is significantly restricted. In addition, the high cost of Capecitabine, the availability of competitors such as raltitrexed and leucovorin, and government rules governing Capecitabine's safety and efficacy all stymie North America capecitabine market expansion.
This research report on the North America Capecitabine Market has been segmented and sub-segmented into the following categories.
By Drug Formulation:
Geographically, North America is estimated to lead the global capecitabine market due to the increased government funding for cancer research; the rising prevalence of different types of cancers in the region, such as breast cancer and colorectal cancer, are expected to fuel the growth of the North America Capecitabine Market.
The U.S Capecitabine Market is predicted to reach a decent CAGR because of the rising incidence of unhealthy lifestyle-induced diseases during the forecast period. Furthermore, a sharp increase in the older population in the United States due to baby boomers led to increased revenue for the region. According to the International Diabetes Federation, over 48 million persons in North America will have diabetes in 2019. More than half of the patients will be over 65, and this trend is likely to continue.
The Canada Capecitabine Market is projected to grow significantly due to increased cancer cases. In addition, physical inactivity, obesity, stress, and a sedentary lifestyle can increase market growth.
KEY MARKET PLAYERS
Companies playing a dominant role in the North America Capecitabine Market profiled in this report are Novartis AG, Sensus Healthcare, RXi Pharmaceuticals, Inc., Revitol Corporation and Avita Medical Limited, Sonoma Pharmaceuticals, Inc., Perrigo Company plc, Bristol-Myers Squibb Company, Valeant Pharmaceuticals International, Inc, Pacific World Corporation.,
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Colon Cancer
5.1.3 Rectal Cancer
5.1.4 Breast Cancer
5.1.5 Gastric Cancer
5.1.7 Y-o-Y Growth Analysis, By Application
5.1.8 Market Attractiveness Analysis, By Application
5.1.9 Market Share Analysis, By Application
5.2 Drug Formulation
5.2.4 Y-o-Y Growth Analysis, By Drug Formulation
5.2.5 Market Attractiveness Analysis, By Drug Formulation
5.2.6 Market Share Analysis, By Drug Formulation
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Application
126.96.36.199 By Drug Formulation
6.1.4 Market Attractiveness Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Application
220.127.116.11 By Drug Formulation
6.1.5 Market Share Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Application
126.96.36.199 By Drug Formulation
6.2 United States
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Novartis AG
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Sensus Healthcare
8.3 RXi Pharmaceuticals Inc.
8.4 Sonoma Pharmaceuticals Inc.
8.5 Perrigo Company plc
8.6 Bristol-Myers Squibb Company
8.7 Pacific World Corporation
8.8 Valeant Pharmaceuticals International Inc.
8.9 Revitol Corporation
8.10 Avita Medical Limited.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.